Pfizer announces positive results from Phase 3 Study of Abrysvo
ABRYSVO met its trial primary endpoints in adults aged 18 to 59 with an increased respiratory syncytial virus (RSV) disease risk.
ABRYSVO met its trial primary endpoints in adults aged 18 to 59 with an increased respiratory syncytial virus (RSV) disease risk.
Approximately half of all patients with metastatic breast cancer (mBC) express low levels of HER2
The companies also plan to collaborate on several early pipeline projects, further technology exploration, and engineering of scalable manufacturing solutions across Novo Nordisk's portfolio
Aims to become a leading global partner for botanical extracts and natural actives in the beauty and personal care market
Fluid bed processes: drying, granulating, and coating in just one product container
The partners will collaborate to build a cutting-edge oligonucleotide cGMP manufacturing facility
The product is bioequivalent and therapeutically equivalent to the Reference Listed Drug (RLD) Prozac Tablets of Eli Lilly
The company will respond to the Warning Letter within the stipulated timelines
Subscribe To Our Newsletter & Stay Updated